Key result
ANGPTL3 inhibitors reduce total cholesterol ~50% in HoFH, outperforming PCSK9 inhibitors.
Why the study?
The study was conducted to compare the efficacy of PCSK9 and ANGPTL3 inhibitors in patients with homozygous familial hypercholesterolemia.
Do ANGPTL3 inhibitors improve lipid profiles in patients with homozygous familial hypercholesterolemia compared to PCSK9 inhibitors?
Do ANGPTL3 inhibitors improve lipid profiles in patients with homozygous familial hypercholesterolemia compared to PCSK9 inhibitors?
In patients with homozygous familial hypercholesterolemia, ANGPTL3 inhibitors demonstrate superior efficacy in reducing lipid levels compared to PCSK9 inhibitors, particularly in those with negative LDLR genotypes.
Supports ANGPTL3 inhibitors over PCSK9 inhibitors for greater TC reduction in HoFH; extends RCT meta-analysis evidence to direct comparison.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bytyçi et al. (2026) studied this question. ANGPTL3 inhibitors achieved a greater reduction in total cholesterol by 49.9% compared to 21.2% for PCSK9 inhibitors in patients with homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: